Scott B. Ullem - 03 May 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Chief Financial Officer
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
03 May 2022
Transactions value $
-$46,715
Form type
4
Filing time
05 May 2022, 17:51:31 UTC
Previous filing
22 Feb 2022
Next filing
10 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Gift $0 -15,488 -42.07% $0 21,324 04 Apr 2022 Direct
transaction EW Common Stock Award $0 +5,000 +23.45% $0 26,324 03 May 2022 Direct F1
transaction EW Common Stock Tax liability -$46,715 -441 -1.68% $105.93 25,883 04 May 2022 Direct
transaction EW Common Stock Gift $0 +15,488 +6.76% $0 244,739 04 Apr 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Award $0 +40,600 $0 40,600 03 May 2022 Common Stock 40,600 $105.93 Direct F2
transaction EW Performance Rights Award $0 +6,250 $0 6,250 03 May 2022 Common Stock 6,250 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F2 These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F3 Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.